Why Tekmira Pharmaceuticals (TKMR) Stock Is Plunging Today

NEW YORK (TheStreet) -- Tekmira Pharmaceuticals  (TKMR) plunged Thursday after the company announced it had received verbal notice from the FDA of a clinical hold on the company's TKM-Ebola Phase I clinical trial.

"We have completed the single ascending dose portion of this study in healthy volunteers without the use of steroid pre-medication," Tekmira said in a statement. "The FDA has requested additional data related to the mechanism of cytokine release, observed at higher doses, which we believe is well understood, and a protocol modification designed to ensure the safety of healthy volunteer subjects, before we proceed with the multiple ascending dose portion of our TKM-Ebola Phase I trial.

"We will continue our dialogue with the FDA, provided for under our Fast Track status, in order to advance the development of this important therapeutic agent."

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 15.68% to $11.61 at 11:56 a.m. More than 1.1 million shares had changed hands by that point, compared to the average volume of 441,864.

TKMR Price Chart

TKMR Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

3 Stocks Pushing The Drugs Industry Lower

Tekmira Pharmaceuticals (TKMR) Weak On High Volume

Tekmira Pharmaceuticals (TKMR): Today's Weak On High Volume Stock

'Mad Money' Lightning Round: Buy, Buy, Buy Yahoo!, Not Alibaba

Jim Cramer's 'Mad Money' Recap: 'Hit and Run' Investors Are the Worst